website - http://www.opexatherapeutics.com/
quote - http://finance.yahoo.com/q/h?s=OPXA
SEC - http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1069308
Opexa Therapeutics, Inc., a development stage biopharmaceutical company, engages in the development and commercialization of autologous cellular therapies for the treatment of multiple sclerosis, rheumatoid arthritis, cardiovascular diseases, and diabetes. These therapies are based on the company's proprietary T-cell and stem cell technologies.
The company's lead product, Tovaxin, is a T-cell-based therapeutic vaccine for multiple sclerosis, which offers an approach to treat the disease by inducing an immune response against the autoimmune myelin-reactive T-cells. Tovaxin is in Phase I/II clinical trials. Opexa Therapeutics also conducts preclinical research to develop stem cell therapies to treat congestive heart failure and Type 1 diabetes, as well as develops rheumatoid arthritis T-cell vaccination technology.
- Overview -
by Opexa - http://www.opexatherapeutics.com/tovaxin.php
by BioCentury -http://www.opexatherapeutics.com/biocentury_10102008.pdf
- Publication Phase I-II_a Trial Results -
- Phase II_b Trial Results -
- Overview -
- Progress to Date -